ALAN J MAIN
CIK 1227372 · EVP, Innov & Chem Sciences · last filed 2025-03-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$540.3K
Companies
2
Total Filings
37
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LXRX | EVP, Innov & Chem Sciences | 281,391 | $1.92 | $540.3K | $0 | 36 | 2025-03-03 |
| LEXICON PHARMACEUTICALS, INC. (LEXG) Delisted | EVP, Pharmaceutical Research | — | — | — | $0 | 1 | 2007-02-15 |
Recent Filings · Page 2 of 4
37 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-04-24 | LXRX | Mixed | +13,080 | -$13.4K | EDGAR |
| 2020-03-03 | LXRX | Mixed | +24,493 | -$35.3K | EDGAR |
| 2020-02-10 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2019-03-01 | LXRX | Mixed | +13,266 | -$37.9K | EDGAR |
| 2019-02-08 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2018-03-02 | LXRX | Mixed | +9,571 | -$42.3K | EDGAR |
| 2018-02-12 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2017-03-01 | LXRX | Mixed | +9,030 | -$88.2K | EDGAR |
| 2017-02-13 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2016-03-02 | LXRX | Mixed | +8,053 | -$43.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.